Introduction
Acromegaly, a complex disorder caused by hypersecretion of growth hormone by somatotrophs in the pituitary gland, often due to a pituitary tumor, 1,2 is associated with significantly impaired quality of life (QoL). 3 Symptoms of acromegaly, which commonly include fatigue, joint pain, snoring, excessive sweating, and headaches, often interfere with daily life activities. 1, 4 Acromegaly-related comorbidities and complications (eg, cardiovascular disease, diabetes, cancer, kidney failure, hypothyroidism, bone/joint abnormalities, and sleep apnea) 1, [5] [6] [7] [8] [9] further contribute to decreased QoL and are associated with a high economic burden 7, 8 and increased mortality risk. 11, 12 Acromegaly treatment guidelines recommend the use of pharmacotherapy as adjuvant therapy in cases of persistent disease following surgery or as primary therapy in cases for which surgery is not feasible. 13 Treatment is aimed at achieving a biochemical target goal of an age-normalized serum insulin-like growth factor-1 value; an additional therapeutic goal is a random growth hormone ,1.0 μg/L, which correlates with control of acromegaly. 13 Recommended treatments include somatostatin analogs (SSAs, eg, octreotide, lanreotide, or pasireotide) or pegvisomant as initial therapy in patients with significant disease, and dopamine agonists (usually cabergoline) for patients with mild to moderate disease. 13 A study using claims data from a database of commercially insured patients from 2006 to 2013 found that over half of patients diagnosed with acromegaly received acromegalyspecific pharmacotherapy, with cabergoline and octreotide prescribed most frequently. 7 Achieving biochemical control has been associated with reduction of symptoms and complications and reduced mortality risk and may improve QoL. 14, 15 Therefore, adherence to therapy is an important component in successful longterm treatment. However, the aforementioned claims database study found that adherence rates to pharmacologic treatment were generally low (,40%); rates of persistence (remaining on therapy for the minimum recommended time) were also low (,65%). 7 The SSAs and pegvisomant are administered parenterally, with dosing frequency that varies from four times per day to once every 4 weeks, which may contribute to nonadherence. 7 Other aspects of acromegaly treatment can be burdensome to patients, such as injection-related signs and symptoms (eg, injection-related pain, which may last several days after injection), emotional impact (eg, some patients report feeling a loss of independence), disruptions to everyday life (eg, inconvenience of transportation to and from the general practitioner's office or clinic to receive injections, work loss, and problems with preparation and administration of injections), 4 or the financial burden of treatment; 7 these burdens may also present barriers to adherence. Finally, some patients may independently discontinue treatment when their acromegaly symptoms appear to resolve or are mild and do not improve with therapy. 16 Establishment of a partnership with health care providers is important to patients, 17 and effective communication may help to improve adherence. 18 In addition, a number of patient education, support, and financial resources are available for patients which may help to overcome some barriers to adherence. 18 A survey was undertaken to assess communication practices, along with awareness and utilization of acromegaly-related patient resources among endocrinologists who currently treat patients with acromegaly.
Materials and methods survey design
A national online survey was developed and administered. A total of 4,280 endocrinologists were randomly selected from the database of 8,301 endocrinologists, based on the CMS National Plan and Provider Enumeration System. United States-licensed physicians were invited by mail to participate in a 20-minute, online national survey. The topic of the survey mentioned on the invitation was generalized to treatments for acromegaly. The eligibility criteria to participate in the survey were as follows: physicians had to be the primary physicians making treatment decisions for at least one patient for their acromegaly. They also had to be willing to provide accurate responses to questions about their professional experiences. It was assumed that participation in this survey was random and represented basic interest and knowledge in acromegaly. No physician data were excluded from the analysis based on their response to the screener questions.
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Data analysis
The individual identities of physician survey respondents were blinded to the study authors. All survey data were analyzed in the aggregate. Responses to the closed questions were analyzed quantitatively. A response that addressed multiple categories was counted as multiple comments. SPSS Version 20 was used. All continuous variables were analyzed using Student's t-test after testing for homogeneity of variance using Levene's Test of Equality of Variances. All categorical variables for which the expected cell frequencies were .5 were analyzed using the Pearson chi-square test. Fisher's exact test was used whenever the expected cell frequencies were #5. P,0.05 was considered significant.
Results

respondents, practice information, patient information, and prescribed treatments
Of the 146 respondents who entered the screener, 133 qualified based on currently being the primary physician making treatment decisions specifically for acromegaly for at least one patient. Results are based on 126 physicians who completed the survey at the time of the analysis. Respondents were mostly (63%) male and in practice for a mean of 17.3 years. Urban and suburban practices were about equally represented; group practice was the most common practice type (50%). Approximately one third of respondents reported an academic affiliation, whereas only 10% were affiliated with a pituitary center ( Table 1) .
Information regarding the respondents' acromegaly patients (ie, those for whom each respondent was the primary physician making treatment decisions) is summarized in Table 1 . Respondents reported managing a median of five acromegaly patients (mean, 11.3). The majority of patients (71%) were aged 30-59 years (data not shown). A total of 70% of patients are currently receiving drug therapy. Of these, .90% are on octreotide (51%), lanreotide (29%), or pasireotide (11%), either alone or in combination with another therapy ( Figure 1A and B). The majority of patients (64%) receive treatment at home.
Physician satisfaction with current treatments and perspective on the impact of patient adherence on therapy outcome A total of 48% of respondents indicated that they were very or extremely satisfied with the efficacy, and 56% were very or extremely satisfied with the safety of currently available acromegaly treatments, but 45% and 39%, respectively, were only somewhat satisfied, and 7% and 6%, respectively, were not very or not at all satisfied.
Nearly half of the respondents thought that the impact of patient adherence on therapy outcome for acromegaly was either not very (41%) or not at all (7%) significant, whereas 
communication with patients
Respondents indicated that 27% of patients speak with a nurse the same day they are diagnosed. However, respondents discussed a patient's support structure (either during diagnosis or when discussing treatment options) with 69% of their patients, on average ( Figure 2 ). There was no difference in these practices between physicians who believe that patient adherence significantly impacts treatment outcome (M=31.2, SD=40.5) and those who believe that it does not (M=22.7, SD=38.7); t(124) =1.208, P=0.229, in terms of the proportion of patients who speak with a nurse the same day they are diagnosed. Similarly, there was no difference in these practices between physicians who believe that patient adherence significantly impacts treatment outcome (M=71.0, SD=38.1) and those who believe that it does not (M=67.2, SD=38.9); t(124) =0.556, P=0.480, in terms of the proportion of patients with whom they discussed a patient's support structure (either during diagnosis or when discussing treatment options). The survey also explored the degree to which physicians recommend programs or practices that may improve patient adherence -automated adherence reminders, a mobile administration program that allows health care providers to deliver injections at home or a convenient location, or a diary for symptom tracking -including whether there is a dedicated nurse who discusses these topics with patients (Table 2) . Most physicians did not have a dedicated nurse to discuss these topics (24% mentioned for automated adherence reminders, 17% for the mobile administration program, and 14% for symptom tracking). There was only a marginal difference between physicians who do or do not believe patient adherence significantly impacts treatment outcome with regard to the percentage having a dedicated nurse to discuss automated adherence reminders: X Awareness and referrals by physicians to patient education/emotional support programs
Only 14% of the respondents indicated that they routinely recommend education/emotional support programs to patients; however, after being presented with a list of nine examples of education/emotional support programs, this increased to 44%, with 40% being familiar with at least one (though not routinely referring patients to any), and 17% not familiar with any ( Figure 3A ). There was no significant difference between the respondents who believe that patient adherence significantly impacts treatment outcome and those who do not in the proportion who routinely refer patients to at least one program, the proportion familiar with at least one program, and the proportion being familiar with any program; X 2 (2, N=126) =0.654, P=0.721. Top patient education and emotional support resources physicians refer 
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Polanco-Briceno et al patients to "Hormone Health Network (www.hormone.org)" and "Pituitary Network Association (www.pituitary.org)," with 21% of respondents referring patients to each of these ( Figure 3B ). An additional 37% are familiar with "Hormone Health Network," but are not routinely referring patients to it, versus an additional 18% familiar with "Pituitary Network Association," but not routinely referring patients to it. Furthermore, 44% mention being familiar with "Pituitary Society (www.pituitary-society.org)" although only 9% routinely refer patients to this. Overall, respondents who believe that patient adherence significantly impacts treatment outcome were more familiar with individual education and emotional support programs compared to those who do not, although they were generally not more likely to routinely refer patients to any of these resources. There was a significant difference in familiarity with "Acromegaly Info (www. acromegalyinfo.com)" (P=0.015, Fisher's exact test) and "Pituitary Disorders (www.pituitarydisorder.net)" (X 2 [2, N=126] =8.769, P=0.012); physicians who believe that patient adherence significantly impacts treatment outcome were significantly more likely than those who do not to be familiar with both resources (33% vs 17% familiar with "Acromegaly Info," respectively, and 35% vs 18% familiar with "Pituitary Disorders," respectively), although there was no difference in routine referrals (11% vs 3% routinely referring to "Acromegaly Info," respectively, and 14% vs 5% routinely referring to "Pituitary Disorders," respectively).
Awareness and referrals by physicians to patient financial support programs As previously described, the vast majority of patients currently receiving drug therapy (.90%; Figure 1A and B) are on octreotide, lanreotide, or pasireotide (alone or in combination with other treatments). The survey inquired about physicians' awareness of financial assistance programs offered by the drug manufacturers. Only 17% of physicians mention routinely recommending financial resources for patients without publicly funded health care. This increases to 25% when presented with a list of examples, although 34% mention being familiar with at least one (though not routinely referring patients to any), and 41% mention not being familiar with any ( Figure 4A and B) . There was no significant difference between respondents who believe that patient adherence significantly impacts treatment outcome and those who do not in the proportion who routinely refer patients to at least one program, the proportion familiar with at least one program (though not routinely referring patients to any), and the proportion being familiar with There was a significant difference in familiarity with and referrals to information found through endocrine societies (P=0.004, Fisher's exact test); physicians who believe that patient adherence has a significant impact on outcomes were more likely to be familiar with these resources compared to those who do not (36% vs 17%, respectively), although there was no difference in routine referrals (6% vs 0%, respectively). Looking specifically at those currently prescribing either octreotide or pasireotide, which are produced by the same manufacturer (n=107), only 13% routinely referred patients to the manufacturer's program, while 32% of physicians were aware of it but did not routinely refer patients to it, and 55% were not familiar with this program. Among those currently Notes: No significant difference between respondents who do and do not believe patient adherence significantly impacts treatment outcome in the proportion who routinely refers patients to at least one program, the proportion familiar with at least one program, and the proportion being familiar with any program, X 2 (2, n=126) =0.654, P=0.721. *Significant overall difference (chi-square P=0.015) between B and C; significant pairwise differences (P,0.05) for "familiar with, but do not routinely refer" and for "not familiar with." # Significant overall difference (chi-square P=0.012) between B and C; significant pairwise differences (P,0.05) for "familiar with, but do not routinely refer" and for "not familiar with. 
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Polanco-Briceno et al prescribing lanreotide (n=69), 29% routinely referred patients to the financial assistance program offered by the manufacturer, while 35% were aware but did not refer patients, and 36% were not familiar with this program.
Discussion
Patients with acromegaly face a significant burden from the symptoms and complications of the disease itself; this burden can be further increased by the need for chronic therapy. In this study, the majority (70%) of patients were currently on treatment, and the vast majority (.90%) of those patients were prescribed SSAs or pegvisomant. Recent claims database studies have also reported SSAs and pegvisomant (collectively) among the most common treatments. 8, 20, 21 All of these treatments are injectable therapies, which can be associated with various patient concerns 18 and difficulties in terms of side effects, adherence, and overall impact on QoL; 4 these treatments are also associated with substantial costs. 7, 8 Thus, adherence to therapy with these commonly prescribed treatments may be challenging for patients. About half of the respondents indicated that they were very or extremely satisfied with the efficacy (48%) and safety (56%) of currently available treatments, and about half of the respondents (52%) indicated that they believe patient treatment adherence has a significant impact on treatment outcomes. Data regarding treatment adherence and outcomes specific to acromegaly are scarce, although one registry study reported that nonadherence accounted for ~20% of patients with uncontrolled disease. 22 There is also evidence suggesting a need for improved adherence to follow-up and monitoring; 23 patients may not be aware of the need for follow-up 24 or may think treatment and/or follow-up are unnecessary due to an absence of subjective symptoms, 16 and the inability to closely monitor patients seems to be associated with a lower rate of treatment and high rate of active disease. 16, 23, 24 From a broader perspective, an association between adherence to therapy and treatment outcomes has been demonstrated in multiple disease states, including chronic diseases, [25] [26] [27] [28] [29] [30] [31] suggesting the same would be true in acromegaly. Although, a recent study using a web-based survey of health care providers with experience in treating acromegaly (n=23) found that 75% were concerned about adherence to pharmacotherapy and identified inconvenience of treatment and financial issues as being among the top barriers to adherence from the provider perspective. 32 The results of this study suggest that it is necessary to increase awareness of the importance of treatment adherence among physicians who treat patients with acromegaly.
Effective communication with patients has been shown to improve medication adherence, 33 and for patients with acromegaly, discussions regarding the diagnosis, patient concerns, treatment and treatment goals, and available resources (such as the ones included in the survey) may help to address potential barriers to adherence 34, 35 and improve the overall treatment experience. 18 Indeed, offering counseling and informing newly diagnosed patients about the acromegaly community are valued by patients. 17 In this study, approximately two thirds of respondents indicated that they discuss a patient's support structure. However, only about one third of their patients speak with a nurse the same day they are diagnosed, respondents (or their dedicated nurses) discuss tools such as adherence reminders with about half of patients, and less than half of respondents routinely refer patients to patient education and support resources. Despite the large percentage of patients for whom respondents prescribed medications that have a financial assistance program offered by the manufacturer (ie, SSAs), only 25% of respondents routinely refer patients to financial resources, and 41% indicated they were not familiar with any of these resources. The finding that there was no significant difference between respondents who believe patient adherence significantly impacts treatment outcome and those who do not in the proportion who routinely refer patients to at least one program or are familiar with at least one program indicates a need to increase awareness among physicians of the different resources available to patients and how patients, nurses, and physicians can collaborate for successful treatment experiences (eg, using approaches described by Plunkett and Barkan). 18 Limitations of this study include possible enrollment bias (participants could be a selected group and not necessarily representative of all endocrinologists) and inherent limitations of self-reported data. Because the survey did not inquire about treatment outcomes, it is not known whether patient treatment outcomes differed depending on whether respondents do or do not discuss and refer patients to the various resources included. The study did not specifically address treatment adherence rates or potential barriers to adherence observed in the respondents' practices. The survey did not gather information regarding a respondent's rationale for not discussing various topics (eg, adherence reminders) or for not referring patients to a support resource that they were familiar with; as such, whether respondents believe the resources are reliable or helpful is not clear. The specific resources included in the survey may not represent a comprehensive list of all resources available, and the degree to which patients find these particular resources useful is not known.
Conclusion
The results of this study suggest an unmet need for increased awareness among endocrinologists with respect to the importance of patient adherence to therapy and the availability of education, support, and financial resources for patients with acromegaly. Additional research is needed to understand which resources patients identify as most helpful, to evaluate barriers to adherence and the effect of utilization of patient resources and medication/disease management tools on treatment adherence, and to quantify the impact of adherence on treatment outcomes for patients with acromegaly.
